melatonin orion 5 mg tabletti
orion corporation - melatonin - tabletti - 5 mg - melatoniini
melatonin orion 3 mg tabletti
orion corporation - melatonin - tabletti - 3 mg - melatoniini
rivaroxaban avansor 2.5 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 2.5 mg - rivaroksabaani
defitelio
gentium s.r.l. - defibrotidia - maksan vajaatoiminta - antitromboottiset aineet - defitelio on tarkoitettu kohtelu vaikea maksan veno-okklusiivinen tauti (vod) tunnetaan myös sinimuotoinen obstruktiivinen oireyhtymä (sos) hematopoeettisten kantasolujen elinsiirrot (potilaat) hoito. se on tarkoitettu aikuisille ja nuorille, lapsille ja vauvoille 1 kuukauden iästä lähtien.
epclusa
gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 ja 5.
wakix
bioprojet pharma - pitolisant - narkolepsia - muut hermoston huumeet - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.
tagrisso
astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
orudis 50 mg kapseli, kova
sanofi oy - ketoprofenum - kapseli, kova - 50 mg - ketoprofeeni
orudis 100 mg peräpuikko
sanofi-aventis oy - ketoprofenum - peräpuikko - 100 mg - ketoprofeeni
orudis 100 mg kapseli, kova
sanofi oy - ketoprofen - kapseli, kova - 100 mg - ketoprofeeni